

Susumu S Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8264278/publications.pdf>

Version: 2024-02-01

62
papers

8,621
citations

159358

30
h-index

149479

56
g-index

63
all docs

63
docs citations

63
times ranked

9759
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. <i>New England Journal of Medicine</i> , 2005, 352, 786-792.	13.9	3,715
2	CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib. <i>Journal of Clinical Oncology</i> , 2011, 29, e443-e445.	0.8	546
3	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology</i> , The, 2012, 13, e23-e31.	5.1	505
4	BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. <i>PLoS Medicine</i> , 2007, 4, e315.	3.9	444
5	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	5.8	438
6	Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. <i>Clinical Lung Cancer</i> , 2009, 10, 281-289.	1.1	394
7	An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 7096-7101.	0.4	250
8	Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 118-122.	0.5	166
9	EGFR-mutated lung cancer: a paradigm of molecular oncology. <i>Oncotarget</i> , 2010, 1, 497-514.	0.8	159
10	Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. <i>Lung Cancer</i> , 2017, 106, 17-21.	0.9	149
11	Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1086-1090.	0.5	148
12	Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance. <i>Cancer Research</i> , 2008, 68, 5827-5838.	0.4	141
13	<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803.	0.8	137
14	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. <i>Cancer Research</i> , 2006, 66, 11389-11398.	0.4	112
15	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and PD-L1 Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 878-883.	0.5	109
16	Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia. <i>Journal of Biological Chemistry</i> , 2002, 277, 33968-33977.	1.6	96
17	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , 2014, 83, 37-43.	0.9	86
18	β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. <i>Cancer Research</i> , 2014, 74, 5891-5902.	0.4	76

#	ARTICLE	IF	CITATIONS
19	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015, 90, 369-374.	0.9	70
20	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1995-2002.	0.5	58
21	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 6548-6555.	3.2	49
22	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. <i>Molecular Cancer Research</i> , 2019, 17, 2233-2243.	1.5	49
23	Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. <i>Cell Reports</i> , 2016, 16, 457-471.	2.9	48
24	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010, 115, 2901-2909.	0.6	46
25	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. <i>Lung Cancer</i> , 2018, 116, 90-95.	0.9	46
26	Targeting transcription factors in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019, 109, 28-34.	0.7	43
27	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. <i>Translational Lung Cancer Research</i> , 2015, 4, 809-15.	1.3	43
28	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
29	Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 21762.	1.6	39
30	The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. <i>Nature</i> , 2021, 600, 319-323.	13.7	37
31	Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 918-923.	0.5	31
32	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 4835-4848.	0.4	31
33	Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118762.	2.6	30
34	Long-read sequencing for non-small-cell lung cancer genomes. <i>Genome Research</i> , 2020, 30, 1243-1257.	2.4	28
35	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100051.	0.6	26
36	Prognostic significance of β -catenin expression in patients with non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, 97-108.	1.3	22

#	ARTICLE	IF	CITATIONS
37	ZNF143 protein is an important regulator of the myeloid transcription factor C/EBP β . <i>Journal of Biological Chemistry</i> , 2017, 292, 18924-18936.	1.6	20
38	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021, 138, 1331-1344.	0.6	19
39	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016, 99, 17-22.	0.9	16
40	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e175-e177.	0.5	15
41	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. <i>Oncologist</i> , 2021, 26, 281-287.	1.9	15
42	A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. <i>Journal of Biomolecular Screening</i> , 2015, 20, 1150-1159.	2.6	14
43	HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR TKIs. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	0.8	14
44	Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100105.	0.6	13
45	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
46	NAD Modulates DNA Methylation and Cell Differentiation. <i>Cells</i> , 2021, 10, 2986.	1.8	12
47	Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100071.	0.6	11
48	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. <i>Clinical Lung Cancer</i> , 2015, 16, e105-e109.	1.1	10
49	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e1-e3.	0.5	8
50	EGFR-D770G and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. <i>Cells</i> , 2021, 10, 3561.	1.8	7
51	Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP β . <i>Molecules</i> , 2018, 23, 1938.	1.7	6
52	CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0120647.	1.1	6
53	Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density. <i>Anticancer Research</i> , 2017, 37, 4779-4788.	0.5	5
54	Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator. <i>International Journal of Hematology</i> , 2020, 112, 395-408.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2286-2289.	1.0	2
56	Abstract 1030: CENP-E inhibition generates micronucleus formation activating the cGAS-STING pathway in cancer cells. , 2021, , .		2
57	Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. <i>Cancer Science</i> , 2021, , .	1.7	1
58	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. <i>Annals of Pharmacotherapy</i> , 2011, 45, 263-275.	0.9	0
59	Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100133.	0.6	0
60	Complete Absence of the Lineage-Determining Transcription Factor C/EBP β Results in Loss of Myeloid Identity in Bcr/abl Induced Malignancy.. <i>Blood</i> , 2005, 106, 646-646.	0.6	0
61	A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 3175-3175.	0.6	0
62	Abstract 5635: Combined MEK and mitophagy inhibition promotes mtDNA-mediated innate immunity in <i>KRAS</i> -mutant cancer. <i>Cancer Research</i> , 2022, 82, 5635-5635.	0.4	0